Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov-Dec;20(6):14791641231197114.
doi: 10.1177/14791641231197114.

Lipoprotein (a) as a predictor of diabetic retinopathy in patients with type 2 diabetes: A systematic review

Mohammad Sadra Gholami Chahkand  1 , Fatemeh Esmaeilpour Moallem  2 , Abolfazl Qezelgachi  3 , Kiana Seifouri  4 , Armin Pesaran Afsharian  5 , Farzad Sheikhzadeh  6 , Atefe Poursalehi  7 , Fateme Sadat Fani Sadrabadi  8 , Mehrnush Saghab Torbati  9 , Mohaddese Ramezanzade  10 , Goharsharieh Alishiri  11 , Arina Ansari  12 , Emad Zare Dehabadi  4 , Saeed Karimi Matloub  13 , Zahra Sheikh  14 , Niloofar Deravi  4 , Saba Mehrtabar  15 , Fatemeh Chichagi  16 , Neda Faal Hamedanchi  17 , Mohammadreza Arzaghi  18 , Mahla Asadi  19 , Parisa Alsadat Dadkhah  3 , Akram Ansari  20
Affiliations

Lipoprotein (a) as a predictor of diabetic retinopathy in patients with type 2 diabetes: A systematic review

Mohammad Sadra Gholami Chahkand et al. Diab Vasc Dis Res. 2023 Nov-Dec.

Abstract

Background: Lipoprotein a (LP(a)), an LDL-like lipoprotein, known as a risk factor for cardiovascular diseases, has a controversial association with diabetic retinopathy in patients with type 2 diabetes-the current systematic review aimed to critically assess the association between LP(a) and diabetic retinopathy.

Methods: A systematic review of relevant studies was conducted after a thorough search in PubMed, Scopus, and Google Scholar electronic databases. We used English observational, case-control, and prospective cohort studies published up to August 2022, including type 2 diabetic patients as the population, diabetic retinopathy as the outcome, and LP(a) as the intervention.

Result: 17 relevant studies, including 4688 patients with diabetes, were included in this systematic review. While in 13 studies, Lipoprotein(a) was recognized as a risk factor for diabetic retinopathy, only three studies reported no evidence of a relationship between the two. Also, another study showed a mixed outcome of the relationship between LP(a) and diabetic retinopathy.

Conclusion: High serum lipoprotein(a) in patients with type 2 diabetes is considered a risk factor for diabetic retinopathy. However, further large-scaled cohort studies are still required to validate this finding.

Keywords: Lipoprotein (a); diabetic retinopathy; systematic review; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
PRISMA flow diagram.
See this image and copyright information in PMC

References

    1. WHO. Diabetes. Global population: WHO. Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes 2021.
    1. Singh SS, Rashid M, Lieverse AG, et al. Lipoprotein(a) plasma levels are not associated with incident microvascular complications in type 2 diabetes mellitus. Diabetologia 2020; 63(6): 1248–1257. - PMC - PubMed
    1. Fong DS, Lloyd Aiello TWG, King GL, et al. Diabetic retinopathy. Diabetes Care 2003; 26: 27. - PubMed
    1. Mohammadi M, Raiegani AAV, Jalali R, et al. The prevalence of retinopathy among type 2 diabetic patients in Iran: a systematic review and meta-analysis. Spring 2019; 20: 79–88. - PubMed
    1. Zheng JCJ, Zhang Q, Xiao X. Novel insights into DNA methylation and its critical implications in diabetic vascular complications. Biosci Rep 2017; 37: BSR20160611. - PMC - PubMed

Publication types

MeSH terms